Allogeneic stem cell transplantation for patients with myelodysplastic syndrome 70 years of age or older: A retrospective study of the MDS subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
Heidenreich, S; Ziagkos, D; De Wreede, Let al.
2017 • In Biology of Blood and Marrow Transplantation, 23, p. 44-52
[en] In this retrospective analysis we evaluated the outcome of 313 patients aged ≥ 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients ≥ 70 years was increasingly performed over time. Although
during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients’ seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P = .01) and 46% (P = .002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS.
Disciplines :
Hematology
Author, co-author :
Heidenreich, S
Ziagkos, D
De Wreede, L
Van Biezen, A
Finke, J
Platzbecker, U
Niederwieser, D
Einsele, H
Bethge, W
Schleuning, M
Beelen, DW
Tischer, J
Nagler, A
Glass, B
Maertens, J
Yanez, L
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
Allogeneic stem cell transplantation for patients with myelodysplastic syndrome 70 years of age or older: A retrospective study of the MDS subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT
Publication date :
2017
Journal title :
Biology of Blood and Marrow Transplantation
ISSN :
1083-8791
eISSN :
1523-6536
Publisher :
Carden Jennings Publishing, Charlottesville, United States - Virginia
1 Germing, U., Strupp, C., Kundgen, A., et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89 (2004), 905–910.
2 Radlund, A., Thiede, T., Hansen, S., Carlsson, M., Engquist, L., Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54 (1995), 153–156.
3 Aul, C., Gattermann, N., Schneider, W., Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82 (1992), 358–367.
4 Neukirchen, J., Schoonen, W.M., Strupp, C., et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res 35 (2011), 1591–1596.
5 Greenberg, P., Cox, C., LeBeau, M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997), 2079–2088.
6 Greenberg, P.L., Tuechler, H., Schanz, J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 (2012), 2454–2465.
7 Della Porta, M.G., Tuechler, H., Malcovati, L., et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 29 (2015), 1502–1513.
8 Alessandrino, E.P., Della Porta, M.G., Bacigalupo, A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112 (2008), 895–902.
9 Deeg, H.J., Scott, B.L., Fang, M., et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 120 (2012), 1398–1408.
10 Garcia-Manero, G., Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 90 (2015), 831–841.
11 Silverman, L.R., Demakos, E.P., Peterson, B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002), 2429–2440.
12 Silverman, L.R., McKenzie, D.R., Peterson, B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006), 3895–3903.
13 Kantarjian, H., Issa, J.P., Rosenfeld, C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006), 1794–1803.
14 Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009), 223–232.
15 Platzbecker, U., Schetelig, J., Finke, J., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 18 (2012), 1415–1421.
16 Bacigalupo, A., Ballen, K., Rizzo, D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15 (2009), 1628–1633.
17 Luger, S.M., Ringden, O., Zhang, M.J., et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 47 (2012), 203–211.
18 Giralt, S., Ballen, K., Rizzo, D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 15 (2009), 367–369.
19 EBMT, MED-AB Forms Manual, A Guide to the completion of the EBMT HSCT Med-AB Forms. Available at: https://www.ebmt.org/Contents/Data-Management/Registrystructure/MED-ABdatacollectionforms/Pages/MED-AB-data-collection-forms.aspx, 2015.
20 Kroger, N., Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 119 (2012), 5632–5639.
21 Sorror, M.L., Sandmaier, B.M., Storer, B.E., et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007), 4246–4254.
22 Sorror, M.L., Maris, M.B., Storb, R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106 (2005), 2912–2919.
23 Zipperer, E., Pelz, D., Nachtkamp, K., et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 94 (2009), 729–732.
24 Shouval, R., Labopin, M., Bondi, O., et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party retrospective data mining study. J Clin Oncol 33 (2015), 3144–3151.
25 ClinicalTrials.gov, DNA hypomethylating agents and lenalidomide in elderly patients with myeloid malignancies in the US. updated 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT02863458, 2015 Accessed August 18, 2016.
26 Lim, Z., Brand, R., Martino, R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28 (2010), 405–411.
27 Spyridonidis, A., Bertz, H., Ihorst, G., Grullich, C., Finke, J., Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or =60 years) with active myeloid malignancies. Blood 105 (2005), 4147–4148.
28 Deschler, B., Binek, K., Ihorst, G., et al. Prognostic factor and quality of life analysis in 160 patients aged > or =60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 16 (2010), 967–975.
29 McClune, B.L., Weisdorf, D.J., Pedersen, T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28 (2010), 1878–1887.
30 Brand, R., Putter, H., van Biezen, A., et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. PLoS One, 8, 2013 e74368.
31 Koreth, J., Pidala, J., Perez, W.S., et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 31 (2013), 2662–2670.
32 ClinicalTrials.gov, 5-Azacytidine treatment versus 5-azacytidine followed by allogeneic stem cell transplantation in elderly patients with Myelodysplastic Syndrome (MDS). updated 2016; Available at https://clinicaltrials.gov/ct2/show/NCT01404741, 2011 Accessed August 18, 2016.
33 ClinicalTrials.gov, Allo vs hypomethylating/best supportive care in MDS (BMT CTN 1102). updated 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT02016781, 2013 Accessed August 18, 2016.
34 ClinicalTrials.gov, Adoptive transfer of haplo-identical DLI for AML and MDS. updated 2016; Available at: https://clinicaltrials.gov/ct2/show/NCT02046122, 2014 Accessed August 18, 2016.
